Kornimate/medical-research-clean huggingface dataset:
neuromodulation techniques in the treatment of chronic tinnitus with hearing loss

Conditions: Tinnitus; Hearing Loss

Summary: this study aimed at trying transcranial magnetic stimulation and transcranial direct current stimulation as potential treatments to decrease tinnitus in patients with significant hearing loss.

tinnitus is a very common condition and affects approximately 15% of the population, disrupting sleep, emotional balance and social life of the patients. acoustic deprivation causes hearing loss and is responsible for a cascade of processes that result in the reorganization of the cortex through a synchronization of neuronal activity related to a cortical re-mapping. consistent with the hypothesis that tinnitus is caused by abnormal activation of the auditory cortex, repetitive transcranial magnetic stimulation (rtms) can temporarily reduce cortical hyperactivity through direct neuromodulation of the temporal cortex. furthermore, studies have shown that transcranial direct current stimulation (tdcs) can also suppress tinnitus. objective: to determine the effectiveness of rtms and tdcs in the treatment of patients with chronic tinnitus and auditory loss. methods: we performed an analytical experimental double-blind study using rtms and tdcs in patients with chronic tinnitus and hearing loss.

Eligibility criteria:
inclusion criteria: * chronic tinnitus * hearing loss exclusion criteria: * neurological diseases * use of drugs affecting the central nervous system * evidence of dementia * clinical diagnosis of depression

Keywords: tinnitus hearing loss transcranial magnetic stimulation transcranial direct current stimulation
depression management project

Conditions: Major Depression; Depression

Summary: the purpose of this study is to determine whether an eight-lesson self-help intervention delivered online will result in a reduction of depressive symptoms.


Eligibility criteria:
inclusion criteria: * participants will be 18 years of age or older, * participants will have regular (\>1 time/week) access to internet and email, with a valid email address, * participants will be fluent or almost fluent in english, and * participants will be looking for information to help themselves, rather than another person. * only those invited to participate will be eligible. exclusion criteria: * participants under 18 years of age, * participants will with sporadic (\< 1 time/week) access to internet and email, * participants who fail to provide an email address, * participants with english difficulties, * participants looking for information to help someone else, and * participants not invited will be ineligible.

Keywords: cognitive behavioral therapy mood management self-help internet
identification of the microcirculation of the caput femoris after fracture of the femoral neck

Conditions: Microcirculation of the Caput Femoris

Summary: this project investigates wether the intra-capsular hematoma, that often occurs after fracture of the femural neck, decreases the capillary blood flow of the caput femoris. during operation the measuring device of the o2c-machine in placed on the joint capsula first and afterwards, after surgical opening of the capsula, on the femur directly. the integral of the microcirculation of both parts of the femur is measured in both settings. so the capillary blood flow is measured with the hematoma still in situ, eventually putting pressure on the caput femoris and after the capsula has been opened, the pressure relieved and the hematoma removed. both measurements are compared for each patient. the o2c-machine measures non-invasive with light waves and laser-doppler. the sounding rod is packed in a sterile tube to prevent any contamination of the operation site.


Eligibility criteria:
inclusion criteria: * medial fracture of the femural neck * surgical treatment (hip replacement) exclusion criteria:polytrauma * pathologic fracture * conservative treatment * soft tissue damage * delay of surgery more than 3 days * immune default * polytrauma

Keywords: microcirculation caput femoris
a study to evaluate a single intravenous dose of motavizumab for the treatment of children hospitalized with respiratory syncytial virus (rsv) illness

Conditions: RSV Illness in ≤12 Months of Participants

Summary: the primary objective of this study is to describe the effect of a single dose of medication compared to placebo in the upper respiratory tract in previously healthy children less than or equal to 12 months of age who are hospitalized with lower respiratory tract illness.

the primary objective of this study is to describe the effect of a single 30 mg/kg or 100 mg/kg intravenous (iv) dose of motavizumab compared to placebo on study drug levels and viral load as measured by cultivatable virus and real-time reverse transcriptase-polymerase chain reaction (rt-pcr) in the upper respiratory tract in previously healthy children ≤12 months of age who are hospitalized with lower respiratory tract illness.

Eligibility criteria:
inclusion criteria: children must meet all of the following criteria: * previously healthy * age less or equal to 12 months at the time of randomization * gestational age more or equal to 36 weeks * hospitalized for lower respiratory tract illness (i.e., rsv bronchiolitis and/or pneumonia) * documented positive rsv test within 48 hours prior to randomization * randomization within 12 hours of the decision to hospitalize a child for rsv illness * written informed consent obtained from the participant's parent(s)/legal guardian exclusion criteria: children must have none of the following: * prior receipt of or receiving ribavirin or other anti-viral treatment for the current episode of rsv infection prior to randomization * any use of systemic or inhaled steroids within the past 30 days prior to randomization * intubation for ventilatory support at randomization * any medically significant underlying ongoing chronic illness or organ system dysfunction, or other known acute illness except for rsv infection * known renal impairment, hepatic dysfunction, hematologic abnormalities, seizure or other neurologic disorder or immunodeficiency * requirement for supplemental oxygen at any time prior to the current rsv infection (brief use of oxygen in the immediate postnatal period to treat a transient condition is allowed) * mechanical ventilation at any time prior to the onset of the current rsv infection * congenital heart disease \[children with medically or surgically closed patent ductus arteriosis (pda), small atrial septal defect (asd) or small ventricular septal defect (vsd) will be allowed\] * previous reaction to ivig, blood products, or other foreign proteins * prior use of intravenous immunoglobulin (ivig), palivizumab (synagisò), or other immunoglobulin products within the past 2 months * currently receiving other investigational agents or have received any other investigational agents within the 3 months prior to randomization * prior or current participation in any investigational study with a therapeutic agent or vaccine for rsv

Keywords: respiratory syncytial virus illness rsv
program in support of moms (prism): a pilot study

Conditions: Perinatal Depression

Summary: the primary goal of this study is to evaluate the program in support of moms (prism) that aims to improve women's access to and participation in perinatal depression treatment and thereby improve depression outcomes

major depressive disorder continues to be the leading cause of disability among women of reproductive age and major public health concern. upwards of 1 in 5 women suffer from depression during pregnancy or within a year after giving birth. it has negative effects on birth outcomes, infant attachment, behavior and development. maternal suicide causes 20% of postpartum deaths in depressed women. although the majority of women are amenable to depression screening, screening alone does not improve treatment entry or outcome. despite the availability of effective evidence-based treatments and frequent contact with obstetric providers, less than one-third of women who screen positive for depression receive treatment. ob/gyn practices need supports in place to adequately address depression in their patient populations. thus, the investigators developed a program called "program in support of moms" (prism) that aims to leverage existing roles and resources to target patient, provider, and system level barriers to perinatal depression treatment. prism aims to improve perinatal depression treatment and treatment response rates through: (1) access to psychiatric telephone consultation for ob/gyn providers; (2) clinic-specific implementation of stepped care, including training support and toolkits; and, (3) proactive treatment engagement, patient monitoring, and stepped treatment response to depression screening/assessment. four practices were randomly assigned to prism versus an active comparison group called mcpap for moms which is a state-wide telephonic perinatal psychiatry program. the investigators will compare the effectiveness of prism vs. mcpap for moms to improve depression severity and treatment participation in pregnancy through 3 months postpartum among patients.

Eligibility criteria:
inclusion criteria: 1. female 2. age 18-55 years 3. english speaking 4. 4-36 weeks gestational age (ga) or 2-12 weeks postpartum 5. receiving care from one of the 4 participating clinics (2 clinics which will participate in prism and 2 with access to mcpap for moms) 6. edinburgh postnatal depression scale score (epds) ≥10 7. able to communicate in written and spoken english; and 8. cognitively able to participate in informed consent exclusion criteria: 1. lack of verbal and written english fluency 2. under age 18 or over age 55 3. current active substance use disorder 4. bipolar disorder diagnosis as determined by the mini-international neuropsychiatric interview (m.i.n.i.) 5. psychotic component to illness as determined by the m.i.n.i.

Keywords: depression pregnancy postpartum
open-label leucovorin pharmacokinetic study in patients receiving high dose methotrexate with or without voraxaze

Conditions: Osteosarcoma; Leukemia; Lymphoma

Summary: the purpose of this study is to investigate whether the administration of voraxaze reduces exposure to leucovorin and its active metabolite to below the level achieved in patients who have not received voraxaze.


Eligibility criteria:
inclusion criteria: * receiving high-dose methotrexate (hdmtx) with or without risk of methotrexate (mtx) toxicity, impaired renal function, and delayed mtx elimination * require intravenous leucovorin exclusion criteria: * arm a only: allergic reactions to lactose * arm a only: hereditary fructose or galactose intolerance * arm b only: delayed elimination of mtx

Keywords: high dose methotrexate voraxaze leucovorin delayed elimination methotrexate toxicity rescue renal insufficiency
effect of fermented maillard reacted whey protein on immune function

Conditions: Immune Deficiency

Summary: to investigate the impact of supplementing fermented maillard reacted whey protein (f-mrp) on natural killer (nk) cell activity, circulating cytokines and serum protein levels.

a randomized, double-blind, placebo-controlled study was conducted on 80 participant without diabetes and obesity. over a 8-week testing period, the f-mrp group consumed 6 g of powder containing 4.2 g f-mrp each day, whereas the placebo group consumed the same amount with dextrin. nk cell activity (%) was measured based on the ratios of effector cells (e; peripheral blood mononuclear cells, pbmcs) from each participant to target cells (t; k562 cells) at e:t= 10:1, 5:1, 2.5:1, or 1.25:1.

Eligibility criteria:
inclusion criteria: * able to give informed consent * the levels of white blood cells within range 3x10\^3/μl\~8x10\^3/μl * males and females * 20-70 years old * without no severe complications exclusion criteria: * diabetes * white blood cell under 3x10\^3/μl or over 8x10\^3/μl * pregnancy or breast-feeding * hypersensitivity or disease history for milk protein * liver disease, inflammation disease, or severe kidney failure disease * cancer, lung disease, leukemia, or autoimmune disease * psychological or neurological disease * myocardiac infarction or cerebrovascular diseases within 6 months before screening * consumption of other test products or drugs within 1 month before screening * inflammation related disease within 1 month before screening

Keywords: fermented maillard reacted whey protein natural killer cell activity immune function pre-albumin interleukin-12
performance study for inferread ct pneumonia.ai

Conditions: Pneumonia

Summary: a retrospective, blineded, multicenter study of the inferread ct pneumonia.ai to evaluate the performance in identifying non-contrast chest ct scans containing pneumonia findings.

this is a retrospective, blinded, multicenter study for the inferread ct pneumonia.ai. the primary endpoint will evaluate the software's performance in identifying non-contrast chest ct scans containing pneumonia. it will evaluate inferread ct pneumonia.ai in terms of sensitivity and specificity with respect to a ground truth, as established by trained thoracic radiologists, in the detection of penumonia. in addition, the study will compare time to notification for the inferread ct pneumonia.ai software with respect to the time to notification for the standard of care as established from available radiological reports. 1. to evaluate the performance of inferread ct pneumonia.ai. 2. to evaluate the effect of different factors such as ct manufacturer, ct scanning protocols and patient characteristics on the performance of inferread ct pneumonia.ai

Eligibility criteria:
inclusion criteria: 1. non-contrast chest ct dicom scans 2. contains both lung lobes 3. slice thickness is less than 3 mm. exclusion criteria: 1. incomplete scan or corrupted scan 2. irregular scanning, increased intrapulmonary density due to insufficient inspiration, and respiratory artifacts affecting the physician's judgment. 3. altered or absent lung morphology in the postoperative patient.
18f-flt pet/ct in measuring cell proliferation in patients with brain tumors

Conditions: Metastatic Malignant Neoplasm in the Brain; Primary Brain Neoplasm; Recurrent Brain Neoplasm

Summary: this pilot clinical trial studies fluorine f 18 fluorothymidine (flt) positron emission tomography (pet)/computed tomography (ct) in measuring cell proliferation in patients with brain tumors. comparing results of diagnostic procedures done before, during, and after treatment may help doctors measure tumor growth and plan the best treatment.

primary objectives: i. using flt pet/ct as a measure of cellular proliferation, assess tissue proliferation in disease sites of brain tumor patients before therapy (surgery, chemotherapy or radiotherapy or any combination of these). ii. determine level of change in cellular proliferation compared with baseline (scan 1) in brain tumors at mid-therapy (scan 2), after completion of therapy (scan 3) and in the clinical follow-up period (scan 4), when possible. iii. correlate levels of cellular proliferation measured by flt pet/ct at baseline and treatment-induced changes in brain tumor proliferation with clinical response status (clinical categories are complete remission, lesser degrees of response/stable disease, and no response). secondary objectives: i. assess spatial heterogeneity of flt uptake to identify local differences in brain tumor disease burden. outline: patients undergo 18f-flt pet/ct at baseline (pre-therapy), mid-therapy, completion of therapy, and 1 year after completion of therapy or time of suspected recurrence. after completion of study, patients are followed for up to 7 years.

Eligibility criteria:
inclusion criteria: * have a diagnosis or suspected diagnoses of brain tumor (primary, recurrent, or metastatic) by standard clinical diagnosis such as pathology or imaging * planned for treatment with radiation, chemotherapy and surgical resection or any of these treatment strategies combined exclusion criteria: * inability to provide informed consent * pregnancy * inability to lie still for the imaging study * weight over 350 lbs.
investigating the role of en in ntis among fistula patients

Conditions: Gastrointestinal Fistula

Summary: the purpose of this study is to investigate whether enteral nutrition are effective in the treatment of nonthyroidal illness syndrome among fistula patients.

nonthyroidal illness syndrome (ntis) is a common alterations in thyroid function observed in about 70% of hospitalized patients, with or without acute systemic illnesses. mechanisms in the pathogenesis of ntis are not yet well understood. our previous study demonstrated that ntis occurred frequently with a prevalence of 57.5% in gastrointestinal fistulas patients. in recent study, it has been shown that early enteral nutrition decreases the duration of hospitalization and mortality in the burn population, indicating a potential role of enteral nutrition in ntis.in addition, the management of fistula patients requires bundle therapy including nutrition therapy, especially enteral nutrition.the purpose of this study is to investigate whether enteral nutrition are effective in the treatment of nonthyroidal illness syndrome among fistula patients.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of gastrointestinal fistula * clinical diagnosis of nonthyroidal illness syndrome * using enteral nutrition for fistula management exclusion criteria: * patients who were prescribed drug which may affect thyroid function before or in our study * patients who were diagnosed as primary thyroid disease

Keywords: gastrointestinal fistula enteral nutrition thyroid function
to evaluate the efficacy and safety of dw-1401 in acute and chronic gastritis patients

Conditions: Gastritis Acute; Gastritis Chronic

Summary: evaluate the efficacy and safety of dw1401 versus stillen tab. in patients with acute or chronic gastritis


Eligibility criteria:
inclusion criteria: * patients who were diagnosed with acute or chronic gastritis in a gastroscopy performed within 7 days prior to administration of this trial. * at least one or more erosions have been identified on gastroscopy. * patients who decided to voluntarily participate in this trial and agreed in writing. exclusion criteria: * patients who can not undergo gastroscopy * peptic ulcer (except scarring) and reflux esophagitis * patients who have had gastric acid suppression surgery or stomach/esophagus surgery (except for simple perforation surgery and appendectomy) * patients with a history of gastrointestinal malignancies * zollinger-ellison syndrome patients * patient with spontaneous coagulation disorder * patients with an allergic or hypersensitive response to a study drug * patients with a potential pregnancy. * patients who had clinically significant abnormalities in the screening test. (alt, ast, bun, serum creatinine is more than twice the upper limit) * pregnant and lactating women * those currently taking other study drugs * patients who were judged to be ineligible for the trial by the principle investigator and the person in charge.
triple tourniquets with or without tranexamic acid for reducing blood loss at open myomectomy

Conditions: Myoma

Summary: in this study, the investigators will investigate the effectiveness of an intravenous tranexamic acid plus triple tourniquets compared with triple tourniquets alone for the reduction of blood loss at the time of myomectomy

an rct investigated the efficacy of intravenous tranexamic acid (ta) during abdominal myomectomy. the study was unable to demonstrate any significant impact on blood loss, duration of surgery or need for blood transfusionhemostatic tourniquets to reduce intra-operative bleeding have long been available, but data on their efficacy from controlled trials are lacking. the investigators set out to evaluate the use of triple tourniquets plus tranexamic acid in controlled conditions and for the first time to investigate the hypothesis that adding tranexamic acid to tourniquet around the uterine artery reduces postoperative bleeding from the uterine incisions, a well-recognized sequel to surgery

Eligibility criteria:
inclusion criteria: * patients presenting for abdominal myomectomy with documented uterine fibroids on ----pelvic imaging * age ≥ 18 years and ≤ 50 years * pre-operative hemoglobin \>8 g/dl * ability to understand and the willingness to sign a written informed consent. * admissible medical/surgical history * five or less symptomatic uterine myomas * all myomas are subserous or intramural. * uterine size less than 24 weeks of pregnancy exclusion criteria: * patients who have had a prior abdominal myomectomy * post-menopausal women * patients with known bleeding/clotting disorders * patients with a history of gynecologic malignancy * hypertension. * cardiac and pulmonary diseases. * obesity (body mass index \> 30 kg/m2). * history of allergic reactions attributed to misoprostol * cases that will require intraoperative conversion of myomectomy to hysterectomy

Keywords: haemostatic tourniquets tranexamic acid myomectomy
influence of air pollution on spondyloarthritis flare-ups and resistance to treatment

Conditions: Spondyloarthritis, Axial

Summary: the relationship between exposure to air pollution and spondyloarthritis (spa) has been poorly studied. based on data from the literature on other inflammatory pathologies such as rheumatoid arthritis, we hypothesize that there is a relationship between exposure to air pollution and the risk of presenting a flare-up in spa patients following and living in franche-comté (france). primary objective:the potential relationship between exposure to air pollution (nitrogen dioxide, fine particles with a diameter of less than 10 or 2.5 microns and ozone) and the onset of a spondyloarthritis flare-up will be explored in patients with this pathology.


Eligibility criteria:
inclusion criteria: * diagnosis of axial spondyloarthritis (radiographic or non-radiographic) according to assessment of spondyloarthritis international society (asas) criteria * patient having received a consultation / hospitalization during the period 2019-2022 * patient enrolled in the mistic cohort * having lived in franche-comté during the 2019-2022 period. exclusion criteria: * other chronic inflammatory rheumatism (rheumatoid arthritis according to acr 2010 criteria or psoriatic arthritis according to classification criteria for psoriatic arthritis criteria) * no inflammatory rheumatic disease

Keywords: air pollution
efficacy and safety study of ta-7284 in patients with type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is to evaluate the efficacy and safety of ta-7284 as monotherapy in patients with type 2 diabetes for 24 weeks administration.

this is a randomized, 3-arm, parallel group, double blind study to evaluate the efficacy and safety of ta-7284 in japanese patients with type 2 diabetes mellitus, who are not optimally controlled on diet and exercise. the patients will receive either ta-7284-low, ta-7284-high or placebo orally alone for 24 weeks.

Eligibility criteria:
inclusion criteria: * men or women age ≥20 years old * diagnosed with type 2 diabetes mellitus at least 3 months before run-in period * hba1c of ≥7.0% and ≤10.0% exclusion criteria: * type i diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, secondary diabetes mellitus * past or current history of severe diabetic complications * fasting plasma glucose \> 270 mg/dl before treatment start * history of hereditary glucose-galactose malabsorption or primary renal glucosuria * patients requiring insulin therapy

Keywords: ta-7284 jnj-28431754 canagliflozin sodium glucose co-transporter (sglt2 inhibitor)